CVRx(US:CVRX)2025-02-04 21:16Revenue Expectations - Total revenue for Q4 2024 is expected to be approximately $15.2 million to $15.3 million, a 35% increase from Q4 2023 revenue of $11.3 million[8] - Full year 2024 total revenue is expected to be in the range of $51.1 million to $51.2 million, representing a 30% increase over 2023 revenue of $39.3 million[10] - U.S. revenue for Q4 2024 is expected to be approximately $14.2 million to $14.3 million, while European revenue is expected to be $1.0 million[8] Operational Metrics - As of December 31, 2024, the company had 223 active implanting centers in the U.S., up from 208 as of September 30, 2024[11] - The number of sales territories in the U.S. increased by three to a total of 48 during Q4 2024[11] Financial Position - Cash and cash equivalents as of December 31, 2024, were $105.9 million[12] - The company issued 869,059 shares of common stock for gross proceeds of $12.8 million under its at-the-market offering during Q4 2024[9] Financial Reporting - The estimated financial results for Q4 and full year 2024 are preliminary and unaudited, with actual results expected to be released in early February 2025[13]